BackRecursion Pharmaceuticals Overview

Recursion Pharmaceuticals Research & Development

Research & Development expenses for RXRX.

Quarterly R&D Expenses

$87.90M
↓ 32.2% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$420.93M
↑ 11.8% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin